{"id":"NCT01226511","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Pediatric Participants With Generalized Anxiety Disorder","officialTitle":"A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2013-02","completion":"2013-06","firstPosted":"2010-10-22","resultsPosted":"2014-03-05","lastUpdate":"2014-03-05"},"enrollment":281,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Anxiety Neuroses","Anxiety States, Neurotic","Neuroses, Anxiety"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["Cymbalta","LY248686"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Duloxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to find out if duloxetine \\[30-120 milligrams (mg)\\] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).","primaryOutcome":{"measure":"Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist","timeFrame":"Baseline, 10 weeks","effectByArm":[{"arm":"Duloxetine (Acute Treatment)","deltaMin":-9.7,"sd":0.502},{"arm":"Placebo (Acute Treatment)","deltaMin":-7.05,"sd":0.5}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":24,"countries":["United States","Mexico","South Africa"]},"refs":{"pmids":["25791145"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":135},"commonTop":["Headache","Nausea","Vomiting","Decreased appetite","Abdominal pain upper"]}}